152 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
7 May 24
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
7:03am
candidates, including azenosertib and ZN-d5; the potential benefits of our product candidatesand the Company’s cash runway. The terms “advancing
8-K
ZNTL
Zentalis Pharmaceuticals Inc
11 Apr 24
Departure of Directors or Certain Officers
7:00am
Financial Officer. Ms. Epperly is eligible to receive severance benefits under her Amended & Restated Employment Agreement, dated February 28, 2023, which
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
development and the potential benefits thereof, including in platinum sensitive ovarian cancer; the potential for our development approach in platinum … ; potential for generating datasets with value-creating potential; potential for combinations including our product candidates and the potential benefits
S-3ASR
EX-1.2
a918xg2o
29 Feb 24
Automatic shelf registration
5:14pm
S-3ASR
wrz3oe
29 Feb 24
Automatic shelf registration
5:14pm
S-3ASR
EX-4.3
y0jcbtqko
29 Feb 24
Automatic shelf registration
5:14pm
8-K
EX-99.1
xo98k
27 Feb 24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
7:04am
8-K
EX-3.1
d8pj6
15 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:12pm